Salix to Buy Santarus for $2.6 Billion for Diabetes Drug

Salix Pharmaceuticals Ltd., a maker of drugs for gastrointestinal diseases, said it will acquire Santarus Inc. for about $2.6 billion to gain treatments for diabetes and heartburn.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.